Bibliographic information
Guideline—
Year of Publication—
Issuing Institution—
Recommendation
Maintained
In patients with confirmed rifampicin-susceptible, isoniazid-resistant tuberculosis (Hr-TB), treatment with rifampicin, ethambutol, pyrazinamide and levofloxacin is recommended for a duration of 6 months
Recommended in favor
Conditional
Certainty of evidence
Very low
Also Featured In
This recommendation also appears in the following guidelines:
Originally Developed
Guideline
WHO guidelines on tuberculosis infection prevention and control: 2019 update
Year2019
InstitutionWHO
Guideline
WHO consolidated guidelines on tuberculosis: module 5: management of tuberculosis in children and adolescents.
Year2022
InstitutionWHO